Baidu
map

Rheumatology:腹腔抗体阳性不会增加系统性硬化症患者的腹腔疾病患病率

2013-07-18 0906siyu dxy

之前的两项研究认为,系统性硬化症(SSc)的腹腔疾病(CD)患病率(8%)高于一般人群(1%)。但是,这些研究存在局限性:样本量少和应用传统的腹腔镜抗体检查方法。目前,能提高精确度的新检测方法已经出现了。针对这一情况,来自美国纽约特种外科医院风湿免疫科的Lindsy J. Forbess等人进行了一项研究,该研究的目的是明确大样本SSc人群的CD患病率,研究方法是更为先进的血清腹腔测试方法,该检测

之前的两项研究认为,系统性硬化症(SSc)的腹腔疾病(CD)患病率(8%)高于一般人群(1%)。但是,这些研究存在局限性:样本量少和应用传统的腹腔镜抗体检查方法。目前,能提高精确度的新检测方法已经出现了。针对这一情况,来自美国纽约特种外科医院风湿免疫科的Lindsy J. Forbess等人进行了一项研究,该研究的目的是明确大样本SSc人群的CD患病率,研究方法是更为先进的血清腹腔测试方法,该检测方法能将腹腔症状和腹腔抗体水平相关联。研究结果在线发布在2013年7月14日星期日 5月的《风湿病学》(Rheumatology)杂志上。与之前发表的两项研究相反,研究者发现,SSc患者中CD患病率低,而且,合并发生的CD不是SSc患者胃肠道不适的常见原因。

研究样本来自于在医院行特殊手术的硬皮病注册表研究存储的72份血清。研究者检测了血清中抗组织转谷氨酰胺酶(传统)和醇溶蛋白肽防脱酰氨基(新)抗体。如果这些抗体中任何一个阳性,则进行抗肌内膜抗体检查、并行小肠内镜检查获得活检标本以进一步证实。注册表中的数据用来验证是否抗体状态和消化道症状相一致。

研究结果如下,研究的SSc人群中腹腔抗体的发现率是3/72(4%)。腹腔抗体阳性的SSc和腹腔抗体阴性的SSc在胃肠道症状方面无显著差异。该研究队列中未发现一例证实的CD。

与之前发表的两项研究相反,研究者发现,SSc患者中CD患病率较低。而且,合并发生的CD不是SSc患者胃肠道不适的常见原因。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016898, encodeId=72c420168988e, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Jan 09 16:53:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948089, encodeId=91a619480899f, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon May 05 16:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982876, encodeId=01da19828e6e9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 21 23:53:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062480, encodeId=b26220624801b, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 14 02:53:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085569, encodeId=53fa2085569e5, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Dec 12 02:53:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250392, encodeId=677a1250392fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627298, encodeId=2040162e2987a, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016898, encodeId=72c420168988e, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Jan 09 16:53:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948089, encodeId=91a619480899f, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon May 05 16:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982876, encodeId=01da19828e6e9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 21 23:53:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062480, encodeId=b26220624801b, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 14 02:53:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085569, encodeId=53fa2085569e5, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Dec 12 02:53:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250392, encodeId=677a1250392fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627298, encodeId=2040162e2987a, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2016898, encodeId=72c420168988e, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Jan 09 16:53:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948089, encodeId=91a619480899f, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon May 05 16:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982876, encodeId=01da19828e6e9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 21 23:53:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062480, encodeId=b26220624801b, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 14 02:53:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085569, encodeId=53fa2085569e5, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Dec 12 02:53:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250392, encodeId=677a1250392fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627298, encodeId=2040162e2987a, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2016898, encodeId=72c420168988e, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Jan 09 16:53:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948089, encodeId=91a619480899f, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon May 05 16:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982876, encodeId=01da19828e6e9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 21 23:53:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062480, encodeId=b26220624801b, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 14 02:53:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085569, encodeId=53fa2085569e5, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Dec 12 02:53:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250392, encodeId=677a1250392fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627298, encodeId=2040162e2987a, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2016898, encodeId=72c420168988e, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Jan 09 16:53:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948089, encodeId=91a619480899f, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon May 05 16:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982876, encodeId=01da19828e6e9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 21 23:53:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062480, encodeId=b26220624801b, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 14 02:53:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085569, encodeId=53fa2085569e5, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Dec 12 02:53:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250392, encodeId=677a1250392fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627298, encodeId=2040162e2987a, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2016898, encodeId=72c420168988e, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Jan 09 16:53:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948089, encodeId=91a619480899f, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon May 05 16:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982876, encodeId=01da19828e6e9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 21 23:53:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062480, encodeId=b26220624801b, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 14 02:53:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085569, encodeId=53fa2085569e5, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Dec 12 02:53:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250392, encodeId=677a1250392fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627298, encodeId=2040162e2987a, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2016898, encodeId=72c420168988e, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Thu Jan 09 16:53:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948089, encodeId=91a619480899f, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon May 05 16:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982876, encodeId=01da19828e6e9, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 21 23:53:00 CST 2013, time=2013-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062480, encodeId=b26220624801b, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 14 02:53:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085569, encodeId=53fa2085569e5, content=<a href='/topic/show?id=649d85602d7' target=_blank style='color:#2F92EE;'>#腹腔疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85602, encryptionId=649d85602d7, topicName=腹腔疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Dec 12 02:53:00 CST 2013, time=2013-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250392, encodeId=677a1250392fb, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627298, encodeId=2040162e2987a, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Sat Jul 20 01:53:00 CST 2013, time=2013-07-20, status=1, ipAttribution=)]

相关资讯

系统性硬化症患者建议每年筛查肺高压

  马德里——一个国际专家小组在欧洲风湿病学大会上表示,对于系统性硬化症患者应该采用经胸部超声心动图检查联合肺功能检查每年进行1次肺动脉高压(PAH)筛查。该专家组同时还呼吁筛查有硬皮病特征的混合型或其他结缔组织病患者。   密歇根大学安娜堡分校硬皮病项目主任DineshKhanna医生表示,这是首次针对系统性硬化症患者进行肺动脉高压筛查提出的循证和共识建议。他们希望这些建议

Rheumatology:近40年间SSc死亡率无下降趋势

    法国一项系统性综述和荟萃分析显示,系统性硬化症(SSc)的汇总标准化死亡比(SMR)为 3.5,且近40年来无显著变化,这提示其为一种严重疾病。须进一步评估现有最新的治疗方法对SSc死亡率的影响。论文发表于《风湿病学》杂志[Rheumatology(Oxford)2012,51(6):1017]。   研究者经检索1960年1月至2010年6月MEDLINE和荷兰医

甲氨蝶呤治疗青少年系统性硬化症有效

来源:医学论坛网   意大利一项研究表明,甲氨蝶呤(MTX)治疗青少年局限性系统性硬化症有效,且患者耐受性良好。该研究论文近期发表于《关节炎与风湿病学》[Arthritis Rheum 2011,63(7):1998]杂志。   在该双盲试验中,青少年局限性系统性硬化症活动期患者被随机(2:1)分为接受口服MTX(15 mg/m2,最大剂量20 mg)或

瑞舒伐他汀可减轻系统性硬化症内皮功能障碍

柏林(EGMN)——在欧洲风湿病学大会(ECR)年会上,匈牙利德布勒森大学的Gabriella Szucs博士报告了首个瑞舒伐他汀治疗系统性硬化症(SS)的研究结果:6个月的瑞舒伐他汀(可定)治疗可显著减轻SS患者内皮功能障碍并降低C-反应蛋白(CRP)水平。 目前对病情持续进展的SS患者病尚无基础用药或缓解病情的治疗药物。内皮功能障碍是SS发病机制的第一步,如果能够改善内皮功能则有可能减缓疾病进

Baidu
map
Baidu
map
Baidu
map